Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Receivables (2017 - 2025)

BeOne Medicines (BEIGF) has disclosed Receivables for 9 consecutive years, with $865.1 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 27.92% to $865.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $865.1 million through Dec 2025, up 27.92% year-over-year, with the annual reading at $865.1 million for FY2025, 27.92% up from the prior year.
  • Receivables for Q4 2025 was $865.1 million at BeOne Medicines, roughly flat from $863.3 million in the prior quarter.
  • The five-year high for Receivables was $865.1 million in Q4 2025, with the low at $80.7 million in Q2 2021.
  • Average Receivables over 5 years is $412.0 million, with a median of $335.4 million recorded in 2023.
  • The sharpest move saw Receivables skyrocketed 628.37% in 2021, then plummeted 63.9% in 2022.
  • Over 5 years, Receivables stood at $488.2 million in 2021, then tumbled by 63.9% to $176.2 million in 2022, then skyrocketed by 104.17% to $359.8 million in 2023, then soared by 87.98% to $676.3 million in 2024, then increased by 27.92% to $865.1 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $865.1 million, $863.3 million, and $770.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.